Clinical trials: Rosacea
Rosacea
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
To compare the bioequivalence of Perrigo's azelaic acid foam product to Finacea Foam for the treatment of Inflammatory Lesions of Rosacea
- Trial name
- NCT02800148
- Testing
- Azelaic acid foam
- Where
- United States
- Volunteers
- 667 people
- Sponsor
- Padagis LLC
Erythematous (Type One) Rosacea
Dose Response Study of Patients With Erythematous Rosacea
The purpose of this study is to evaluate the dose-response relationship (effect) of four concentrations of V-101 Cream in patients with erythematous(redness) rosacea.
- Trial name
- NCT01186068
- Testing
- V-101, vehicle
- Where
- 7 sites in United States
- Volunteers
- 175 people
- Sponsor
- Vicept Therapeutics, Inc.
Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)
Brimonidine 0.33% for Rosacea-Related Facial Erythema
This study looks at whether a topical gel called 0.33% brimonidine can reduce persistent facial redness caused by rosacea. The study was carried out in two parts.
- Trial name
- NCT07431476
- Testing
- Brimonidine 0.33% gel
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Istanbul Training and Research Hospital
Rosacea
MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to…
- Trial name
- MOSAIC (NCT02616250)
- Testing
- Brimonidine 0.33% gel (Br), Ivermectin 1% cream (IVM)
- Where
- 13 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Galderma R&D
Rosacea
Mirvaso in Use Study
This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2.
- Trial name
- NCT02249065
- Testing
- Brimonidine
- Where
- 12 sites in United States
- Volunteers
- 205 people
- Sponsor
- Galderma R&D
Seborrheic Dermatitis, Papulopustular Rosacea
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai.
- Trial name
- NCT06013371
- Testing
- PF-07038124
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.
- Trial name
- NCT02393937
- Testing
- Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%
- Where
- 27 sites in United States
- Volunteers
- 963 people
- Sponsor
- bioRASI, LLC
Rosacea
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo
The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.
- Trial name
- NCT01426269
- Testing
- Doxycycline, Metronidazole
- Where
- 11 sites in United States
- Volunteers
- 235 people
- Sponsor
- Galderma R&D
Rosacea
Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with…
- Trial name
- NCT03380390
- Testing
- Oxymetazoline HCL 1.0% Cream, Energy-Based Therapy
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Aclaris Therapeutics, Inc.
Facial Rosacea
Clinical Study of a Facial Cream for Rosacea
This study aimed to evaluate the efficacy, tolerability, and safety of Eucerin Skin Relief Multi-Repair Cream containing the active ingredient SenSiCel™ in improving facial rosacea.
- Trial name
- NCT07637032
- Testing
- ARM 1, ARM 2
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- ChinaNorm
Papulopustular Rosacea
A Safety and Efficacy Study to Evaluate Rosacea
To evaluate the safety, efficacy, and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with rosacea.
- Trial name
- NCT03883945
- Testing
- AIV001, Vehicle
- Where
- United States
- Sponsor
- AiViva BioPharma, Inc.
Rosacea
A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
Clinical assessments of efficacy will be conducted based on Investigator's Global Assessment (IGA, modified scale without erythema), Clinician's Erythema Assessment (CEA), and on inflammatory lesion counts at Weeks 4, 8, 12 and…
- Trial name
- NCT03340961
- Testing
- DFD-29 Extended Release Capsules (40 mg), DFD-29 Extended Release Capsules (20 mg), Oraycea® (doxycycline) Capsules
- Where
- 14 sites in Germany
- Volunteers
- 205 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Papulopustular Rosacea
A 21 Day Pharmacokinetics Study in Papulopustular Rosacea
The purpose of this study is to characterize the pharmacokinetics of once daily topical gel and confirm that steady state conditions are reached under maximal use conditions following 3 weeks of daily applications.
- Trial name
- NCT02028286
- Testing
- CLS001
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Rosacea
Genetic Basis of Rosacea Study (Control)
Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. It it considered to be a syndrome encompassing various combinations of cutaneous signs including…
- Trial name
- NCT02749786
- Testing
- Skin Biopsy
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Rosacea
A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea
The objectives of this study were to compare the safety and efficacy profiles of a generic Azelaic Acid Foam, 15% to the reference listed Finacea® (azelaic acid) Foam, 15% and to demonstrate therapeutic equivalence and safety of…
- Trial name
- NCT03287791
- Testing
- Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam
- Where
- 26 sites in United States
- Volunteers
- 924 people
- Sponsor
- Actavis Inc.
Rosacea
Assessment of Rosacea Patients' Clinical Trial Experiences
Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
- Trial name
- NCT05747391
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Rosacea
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
- Trial name
- NCT03689010
- Testing
- Azelaic acid foam 15%, Finacea® (Azelaic acid Foam) 15%, Vehicle of the test product
- Where
- United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.